Champions Oncology, Inc. (CSBR)

Over the past six months, Champions Oncology, Inc.'s stock price has experienced a decline. As of March 26, 2026, the share price was $5.78, representing a 39.16% decline from $9.50 on March 27, 2025. Key events impacting the stock price include the release of second-quarter fiscal 2026 financial results in December 2025, the announcement of third-quarter fiscal 2026 financial results in March 2026, the appointment of Brian Alexander to its Board in March 2026, and the announcement of new data presentations at the 2026 AACR Annual Meeting in April 2026.

Specific detailed information on demand seasonality for Champions Oncology, Inc.'s products and services is not publicly available. The company's CEO has stated that their business can vary period to period, but they manage and evaluate performance primarily on an annual basis. The company also expressed cautious optimism that the pharma and biotech funding environment is beginning to strengthen, which should support improved bookings.

Champions Oncology, Inc. is a technology-enabled research company specializing in advanced oncology research solutions for drug discovery and development, operating within the Healthcare sector, specifically in the Biotechnology industry. The company's core business revolves around its proprietary TumorGraft technology platform, which involves implanting human tumors in immune-deficient mice to provide personalized cancer care insights. Its major products and services include the TumorGraft Technology Platform, Translational Oncology Solutions, Lumin Bioinformatics, and Oncology Research Services.

Champions Oncology, Inc. is headquartered in Hackensack, New Jersey, USA, and has a global reach with clinical sites, laboratories, and a scientific team strategically distributed worldwide. It operates through several subsidiaries, including Champions Oncology (Israel), Limited, Champions Oncology U.K. Limited, Champions Oncology, S.R.L. (Italy), and Corellia A.I. Inc.

In the past year, Champions Oncology has maintained a reputation focused on scientific excellence and innovation in oncology research. The company presented new data at major conferences, demonstrating its ongoing scientific contributions. The appointment of Brian Alexander to the Board reinforces the company's commitment to a data-driven oncology strategy. Champions Oncology emphasizes sustainable business practices, staff wellness, gender equality, diversity inclusion, and reducing its environmental footprint, which positively contributes to its brand reputation.

The ownership structure of Champions Oncology (CSBR) stock is a mix of institutional, insider, and retail investors. Approximately 32.87% to 38.21% of the company's stock is owned by Institutional Investors, 14.82% by Insiders, and 46.97% by Public Companies and Individual Investors. Major institutional owners include Battery Management Corp., NEA Management Company, LLC, and Vanguard Group Inc. Joel Ackerman owns the most shares among individual investors.